Onco Actu du 9 septembre 2016

	2. Etiologie
No, Apple's new AirPods won't give you cancer, experts say [LA Times] The unplugged user’s exposure to electromagnetic radiation “is absolutely minimal — smaller by a huge amount than the exposure of putting a phone to your ear,” Foster said.
	3.1 Tabac
Smoking and Drinking Rates Among U.S. Teenagers Fall to New Lows [NY Times] The trends among teenagers were encouraging, experts said, but other data in a national survey pointed to persistent prescription drug abuse by Americans.
	3.2 Prévention - Obésité
The public doesn’t know obesity causes cancer, and that’s really worrying [Cancer Research UK] To help bridge this gap, it’s important that public health messages and the ways that Government initiatives are targeted and tailored ensure equal access to health information for everyone.
Three in four don’t know obesity causes cancer [Cancer Research UK] As well as general ignorance about obesity and cancer, the survey showed that more than three-quarters (78 per cent) of those asked didn’t know obesity was linked specifically to ovarian cancer.
Three in four Britons unclear on obesity link to​​ cancer – poll [The Guardian] Men and poorer people are most likely not to know about the connection. However, almost 80% of women are unaware that being dangerously overweight can cause female-only forms of cancer such as ovarian and womb cancer.
	3.3 Prévention - Vaccins
France most skeptical country about vaccine safety [Science] “I didn’t expect France to be as negative as it was,” says Larson, who runs The Vaccine Confidence Project, a nonprofit that monitors public concerns about immunization. At the other end of the scale, only 0.2% of the respondents in Bangladesh had similar safety misgivings.
Mistrust of vaccines is greatest in France: survey [Reuters] France - the birthplace of immunology pioneer Louis Pasteur - was the country least confident of vaccine safety, with 41 percent of those surveyed disagreeing that vaccines are safe, more than three times the global average of 12 percent.
	4. Dépistage, diagnostic et pronostic
Spotting the earliest signs of oesophageal cancer with a fluorescence-detecting camera [Cancer Research UK] We’ve carefully tested the device in the lab to see if it might be able to spot the unhealthy cells. This includes pinpointing the smallest object the endoscope can detect (its resolution), the smallest amount of dye it can detect (its sensitivity) and the largest object that can be seen in a single image. And so far these lab tests are showing promise.
	5.12.1 Immunothérapies - partenariats
Fate partners with Memorial Sloan Kettering on off-the-shelf CAR-T [FierceBiotech] The off-the-shelf approach that Fate and Memorial Sloan Kettering are pursuing is already being employed by various companies including Pfizer and Kite Therapeutics.
	5.12.2 Immunothérapies - CAR-T
Juno posts positive lymphoma response data from a small CAR-T trial [FierceBiotech] “This study shows that at the right dose of CAR T cells and lymphodepletion, we can achieve very good response rates for NHL patients who have no other treatment options,” explained Dr. Cameron Turtle, an immunotherapy researcher at the Fred Hutchinson Cancer Research Center and one of the study leaders.
Extra chemo boosts immune cell therapy in lymphoma [Cancer Research UK] Published in the journal Science Translational Medicine, the findings could also have important implications for future trials involving so-called CAR-T cell therapy.
Just how confident is Arie Belldegrun about Kite’s position in the turbulent CAR-T race? He’s glad you asked. [Endpoints news] He also is bullish about Kite’s initial work across all CD19-positive cells, seeing Juno and Novartis’ initial approach to ALL as too limiting. And he expects the field to continue to make dramatic leaps that will continue to disrupt the competitive landscape.
	5.2 Pharma
New analysis showed dose adjustment of Giotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer [Boehringer Ingelheim] A new analysis from two Phase III trials published in Annals of Oncology showed that adjusting afatinib dosing based on tolerability reduced the incidence and severity of treatment-related adverse events with no apparent impact on efficacy.
	5.4 Traitements - Economie
Fixing Drug Pricing Means Paying For “Value” (Ctd.) [The Incidental Economist] The first post in this series made an argument that drug pricing should be tied to value and offered an idea for how we might think about paying for curative therapies. In this post, I’ll focus on pricing ideas for innovative drugs that aren’t curative, as well as generic drugs.
	5.5 ASCO
2016 Symposium Highlights Notable Research Advances in Palliative Care [ASCO] These notable abstracts explore the integration of palliative care to improve patients’ quality of life, as well as insight and approaches for educating oncology providers on how to more effectively communicate and deliver palliative care to their patients.
	6. Lutte contre les cancers
New Report Reveals Gaps, Identifies Unique Barriers in Pediatric Cancer Research [ACS] Analysis Highlights the Importance of Safeguarding Long-term Health of Pediatric Cancer Survivors.
NHS England sets out its vision for personalised medicine [PHG Foundation] The report is a welcome indication that NHS England has made the development of personalised medicine a clear priority. This is an important first step. It does not outline any new commitments but provides a useful overview for the public of NHS England’s current personalised medicine-related activities, including the 100,000 Genomes Project and the 13 Genomic Medicine Centres (GMCs).
	6.10.1 Politiques (USA)
Tyler Jacks, Cancer Moonshot Panel Co-Chair, Discusses Roadmap [Xconomy] We’re actually proposing a scientific network to create better access to clinical materials. Immunotherapy is on fire, it’s taking over the field of cancer. This particular recommendation tries to improve our understanding why certain patients respond and others fail.
Expert Panel Releases Recommendations to Support Cancer Moonshot Initiative [Cancer Research Catalyst] These recommendations, created by a team of the nation’s leading cancer experts, are designed to support Vice President Biden’s National Cancer Moonshot Initiative, which aims to make a decade’s worth of progress in five years.
	6.6 Publications
New Citation Measure Assesses Impact of Single Papers [The Scientist] “I am convinced that here is a metric that reflects how science really evolves in laboratories, scientific meetings, and in obscure journals,” wrote Stefano Bertuzzi, Executive Director of the American Society for Cell Biology.
EU institutions are investigating several papers [Retraction Watch] The National Center for Scientific Research (CNRS) in France will lead the inquiry, with contribution from ETH Zürich in Switzerland. Molecular biology researchers from both institutions were involved in the flagged publications, an ETH Zürich spokesperson told us.
How Much Does Publishing Cost? [The Scholarly Kitchen] In my view, we don’t have to decide which method is better: viewing publishing as simply a production process or viewing it as a matter of careful selection, whose success is measured by marketplace demand. Over time these two processes will either eliminate the other or each find its own place.